The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells
Open accessAbstract
Glioblastomas are lethal cancers characterized by florid angiogenesis promoted in part by glioma stem cells (GSCs). Because hypoxia regulates angiogenesis, we examined hypoxic responses in GSCs. We now demonstrate that hypoxia-inducible factor HIF2alpha and multiple HIF-regulated genes are preferentially expressed in GSCs in comparison to non-stem tumor cells and normal neural progenitors. In tumor specimens, HIF2alpha colocalizes with cancer stem cell markers. Targeting HIFs in GSCs inhibits self-renewal, proliferation, and survival in vitro, and attenuates tumor initiation potential of GSCs in vivo. Analysis of a molecular database reveals that HIF2A expression correlates with poor glioma patient survival. Our results demonstrate that GSCs differentially respond to hypoxia with distinct HIF induction patterns, and HIF2alpha might represent a promising target for antiglioblastoma therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since HIF-2α is strongly expressed in the cytoplasm of NB tumor cells at physiological oxygen levels (5% O2), this could suggest additional largely unexplored functions of HIF-2α in the cytoplasm, independent of HIF-1β-dependent transcription, such as regulation of mRNA translation [9,43].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In NB clinical specimens, HIF-1α expression negatively correlates with the presence of blood vessels indicating that HIF-1α is expressed exclusively in hypoxic cells [43].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, HIF-2α is located in dense clusters of cells adjacent to blood vessels, referred to as the perivascular niche, which have a neural crest-like phenotype, and are HIF-1α negative, suggesting they are not hypoxic [43].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, treatment with PT2385 had no effect on tumor growth, did not impact transcription of HIF target genes and did not modulate chemotherapy response [43].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [43]
Experimental — accuracy not yet measuredIn the citing paper
“Given that HIF-2α is an important transcription factor in cancer progression and leads to poor prognosis69,70”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [70]
In the citing paper
“Hypoxia was first shown to induce the CSC phenotype in glioma [77] and, subsequently, in breast cancer [78, 79], in a HIF-dependent manner.”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C. E., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,564
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517
Self-citationHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., Vitis, S. D., Fiocco, R., Foroni, C., DiMeco, F., & Vescovi, A. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1364 · Cited by 2,570
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,262
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C. R., Poppleton, H., Koçak, M., Hogg, T. L., Fuller, C. E., Hamner, J. B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,253
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., Lu, L., Irvin, D. K., Black, K. L., & Yu, J. S. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-67 · Cited by 1,844
Cancerous stem cells can arise from pediatric brain tumors
Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M. D., Geschwind, D. H., Bronner-Fraser, M. E., & Kornblum, H. I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036535100 · Cited by 1,842
Flagged first, then by citations
1 of the 65 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 1,000
Hypoxia, pseudohypoxia and cellular differentiation
Mohlin, S., Wigerup, C., Jögi, A., & Påhlman, S. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.007 · Cited by 54
Targeting cancer stem cells as therapeutic approach in the treatment of colorectal cancer
Parizadeh, S. M., Esfehani, R. J., Hassanian, S. M., Parizadeh, S. M. R., Vojdani, S., Ghandehari, M., Ghazaghi, A., Khazaei, M., Shahidsales, S., Rezayi, M., et al. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.02.010 · Cited by 53
Ervin, E.-H., French, R., Chang, C., & Pauklin, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.001 · Cited by 53
Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer
Cotino‐Nájera, S., Herrera, L. A., Domínguez-Gómez, G., & Díaz‐Chávez, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1287505 · Cited by 54
Curtis, V. F., Wang, H., Yang, P., McLendon, R. E., Li, X., Zhou, Q., & Wang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054916 · Cited by 57
Self-citationMiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3
Liu, H., Li, C., Shen, C., Yin, F., Wang, K., Liu, Y., Zheng, B., Zhang, W., Hou, X., Chen, X., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1736-y · Cited by 52
Ketkaew, Y., Osathanon, T., Pavasant, P., & Sooampon, S. (2016) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2016.11.010 · Cited by 52
A map of the altered glioma metabolism
Deshmukh, R. S., Allega, M. F., & Tardito, S. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.07.011 · Cited by 53
Kouri, F. M., Ritner, C., & Stegh, A. H. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1093711 · Cited by 52
Hypoxia and succinate antagonize 2-deoxyglucose effects on glioblastoma
Pistollato, F., Abbadi, S., Rampazzo, E., Viola, G., Puppa, A. D., Cavallini, L., Frasson, C., Persano, L., Panchision, D. M., & Basso, G. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.003 · Cited by 51
α2,6 Sialylation mediated by ST6GAL1 promotes glioblastoma growth
Sajina, G. C., Tuy, K., Rickenbacker, L., Jones, R., Chakraborty, A., Miller, C. R., Beierle, E. A., Hanumanthu, V. S., Tran, A. N., Mobley, J. A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158799 · Cited by 51
Self-citationFujikuni, N., Yamamoto, H., Tanabe, K., Naito, Y., Sakamoto, N., Tanaka, Y., Yanagihara, K., Oue, N., Yasui, W., & Ohdan, H. (2014) · Cancer Science · doi:10.1111/cas.12522 · Cited by 51
Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
Ahluwalia, M. S., & Gladson, C. L. (2010) · Journal of Oncology · doi:10.1155/2010/689018 · Cited by 55
Wouters, J., Stas, M., Gremeaux, L., Govaere, O., den broeck, A. V., Maes, H., Agostinis, P., Roskams, T., van den Oord, J. J., & Vankelecom, H. E. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076550 · Cited by 52
Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy
Ning, J., & Wakimoto, H. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00303 · Cited by 52
HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation
Nardinocchi, L., Puca, R., & D’Orazi, G. (2011) · Aging · doi:10.18632/aging.100254 · Cited by 51
Yao, J., Chakhoyan, A., Nathanson, D. A., Yong, W. H., Salamon, N., Raymond, C., Mareninov, S., Lai, A., Nghiemphu, P. L., Prins, R. M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz078 · Cited by 51
Yuan, D., Tao, Y., Chen, G., & Shi, T. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0363-1 · Cited by 53
Tang, J., Amin, M. A., & Campian, J. L. (2025) · Cells · doi:10.3390/cells14080562 · Cited by 55
Exploring metabolic pathways that contribute to the stem cell phenotype
Vacanti, N. M., & Metallo, C. M. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.08.007 · Cited by 51
Womeldorff, M. R., Gillespie, D. L., & Jensen, R. L. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14496 · Cited by 51
A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy
Mao, Q., Zhang, Y., Fu, X., Xue, J., Guo, W., Meng, M., Zhou, Z., Mo, X., & Lü, Y. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1310-3 · Cited by 50
Iriondo, O., Rábano, M., Domenici, G., Carlevaris, O., López-Ruiz, J. A., Zabalza, I., Berra, E., & Vivanco, M. D. (2015) · Oncotarget · doi:10.18632/oncotarget.5564 · Cited by 52
Mirabello, V., Cortezon‐Tamarit, F., & Pascu, S. I. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00027 · Cited by 50
Cellular Reprogramming as a Therapeutic Target in Cancer
Xiong, S., Ye, F., & Cheng, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.05.001 · Cited by 52
Tay, A. S. S., Amano, T., Edwards, L., Zhang, L., de Peralta‐Venturina, M., & Yu, J. S. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.019 · Cited by 50
Zhang, H., Steed, A., Co, M., & Chen, X. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.32 · Cited by 50
Cimino, P. J., Kim, Y., Wu, H., Alexander, J., Wirsching, H., Szulzewsky, F., Pitter, K. L., Ozawa, T., Wang, J., Vazquez, J., et al. (2018) · Genes & Development · doi:10.1101/gad.312157.118 · Cited by 52
Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease
Wu, H. H. L., & Chinnadurai, R. (2022) · Kidney Diseases · doi:10.1159/000521162 · Cited by 49
Smith, S. J., Wilson, M., Ward, J. H., Rahman, C. V., Peet, A. C., Macarthur, D., Rose, F. R. A. J., Grundy, R. G., & Rahman, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052335 · Cited by 51
Bischof, J., Westhoff, M., Wagner, J. E., Halatsch, M., Trentmann, S., Knippschild, U., Wirtz, C. R., & Burster, T. (2017) · Tumor Biology · doi:10.1177/1010428317692227 · Cited by 49
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma
Shiraki, Y., Mii, S., Enomoto, A., Momota, H., Han, Y., Kato, T., Ushida, K., Kato, A., Asai, N., Murakumo, Y., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4981 · Cited by 49
Glioblastoma Stem Cells and Their Microenvironment
Sattiraju, A., Sai, K. K. S., & Mintz, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-69194-7_7 · Cited by 51
USP33 deubiquitinates and stabilizes HIF‐2alpha to promote hypoxia response in glioma stem cells
Zhang, A., Huang, Z., Tao, W., Zhai, K., Wu, Q., Rich, J. N., Zhou, W., & Bao, S. (2022) · The EMBO Journal · doi:10.15252/embj.2021109187 · Cited by 49
Self-citationMiao, Z., Wang, Z.-N., Zhao, T., Xu, Y., Gao, J., Miao, F., & Xu, H. (2014) · Stem Cells · doi:10.1002/stem.1816 · Cited by 49
Mendes, F. A., Aguiar, J. M. C., Kahn, S. A., Reis, A. H., Dubois, L. G., Romão, L. F., Ferreira, L. S. S., Chneiweiss, H., Moura‐Neto, V., & Abreu, J. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133689 · Cited by 48
The complement system in glioblastoma multiforme
van der Vlis, T. A. M. B., Kros, J. M., Mustafa, D. A. M., van Wijck, R. T. A., Ackermans, L. P. C. M., van Hagen, P. M., & van der Spek, P. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0591-4 · Cited by 50
Wang, P., Gong, S., Liao, B., Pan, J., Wang, J., Zou, D., Zhao, L., Xiong, S., Deng, Y., Yan, Q., et al. (2021) · Journal of Cancer · doi:10.7150/jca.54402 · Cited by 47
Brain Cancer Stem Cells: Current Status on Glioblastoma Multiforme
Facchino, S., Abdouh, M., & Bernier, G. (2011) · Cancers · doi:10.3390/cancers3021777 · Cited by 47
Bao, B., Ahmad, A., Li, Y., Azmi, A. S., Ali, S. S., Banerjee, S., Kong, D., & Sarkar, F. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.714774 · Cited by 47
Wang, R., Geller, D. A., Wink, D. A., Cheng, B., & Billiar, T. R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14838 · Cited by 47
Berg, T. J., Marques, C., Pantazopoulou, V., Johansson, E., von Stedingk, K., Lindgren, D., Jeannot, P., Pietras, E. J., Bergström, T., Swartling, F. J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1785 · Cited by 47
Gao, X.-Y., Zang, J., Zheng, M., Zhang, Y.-F., Yue, K., Cao, X., Cao, Y., Li, X.-X., Han, H., Jiang, X., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.620883 · Cited by 49
Self-citationGlioblastoma modeling with 3D organoids: progress and challenges
Wang, X., Sun, Y., Zhang, D. Y., Ming, G.-L., & Song, H. (2023) · Oxford Open Neuroscience · doi:10.1093/oons/kvad008 · Cited by 46
Rewiring of purine metabolism in response to acidosis stress in glioma stem cells
Xu, X., Wang, L., Zang, Q., Li, S., Li, L., Wang, Z., He, J., Qiang, B., Han, W., Zhang, R., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03543-9 · Cited by 47
Wei, Y., Chen, Q., Huang, S., Liu, Y., Li, Y., Xing, Y., Shi, D., Xu, W., Liu, W.-T., Ji, Z., et al. (2022) · Advanced Science · doi:10.1002/advs.202202216 · Cited by 46
Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells
Bai, Y., Lathia, J. D., Zhang, P., Flavahan, W. A., Rich, J. N., & Mattson, M. P. (2014) · Glia · doi:10.1002/glia.22708 · Cited by 49
Self-citationRefined control of cell stemness allowed animal evolution in the oxic realm
Hammarlund, E. U., von Stedingk, K., & Påhlman, S. (2018) · Nature Ecology & Evolution · doi:10.1038/s41559-017-0410-5 · Cited by 46
MicroRNAs, Hypoxia and the Stem-Like State as Contributors to Cancer Aggressiveness
Macharia, L. W., Muriithi, W., Mureithi, M., Pereira, C. M., Ferrer, V. P., & Moura‐Neto, V. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00125 · Cited by 46
de Castro, J. V., Gonçalves, C. S., Hormigo, A., & Costa, B. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155278 · Cited by 47
Renfrow, J. J., Soike, M. H., West, J. L., Ramkissoon, S. H., Metheny-Barlow, L., Mott, R. T., Kittel, C. A., D’Agostino, R. B., Tatter, S. B., Laxton, A. W., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72290-2 · Cited by 45
Emerging role of interactions between tumor angiogenesis and cancer stem cells
Lv, S., Liu, Y., Xie, C., Xue, C., Du, S., & Yao, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.036 · Cited by 45
Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition
Mehta, M., Khan, A. J., Danish, S. F., Haffty, B. G., & Sabaawy, H. E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0708 · Cited by 47
Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling
Gao, P., Yang, C., Nesvick, C. L., Feldman, M. J., Sizdahkhani, S., Liu, H., Chu, H., Yang, F., Tang, L., Tian, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7710 · Cited by 45
Metabolic regulation of glioma stem-like cells in the tumor micro-environment
Thomas, T. M., & Yu, J. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.014 · Cited by 48
Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma
Birch, J. L., Coull, B. J., Spender, L. C., Watt, C., Willison, A., Syed, N., Chalmers, A. J., Hossain-Ibrahim, M. K., & Inman, G. J. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109638 · Cited by 45
Wang, Y., Liu, X., Huang, W., Liang, J., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108303 · Cited by 44
Targeting the perivascular niche in brain tumors
Seano, G. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000417 · Cited by 45
Int6/eIF3e Is Essential for Proliferation and Survival of Human Glioblastoma Cells
Sesen, J., Cammas, A., Scotland, S., Elefterion, B., Lemarié, A., Millevoi, S., Mathew, L. K., Seva, C., Toulas, C., Moyal, E. C., et al. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15022172 · Cited by 45
Hypoxia-induced HMGB1 promotes glioma stem cells self-renewal and tumorigenicity via RAGE
Ye, C., Li, H., Li, Y., Zhang, Y., Liu, G., Mi, H., Li, H., Xiao, Q., Niu, L., & Yu, X. (2022) · iScience · doi:10.1016/j.isci.2022.104872 · Cited by 43
Physicochemical aspects of the tumour microenvironment as drivers of vasculogenic mimicry
Andreucci, E., Peppicelli, S., Ruzzolini, J., Bianchini, F., & Calorini, L. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10067-x · Cited by 44
Role of the tissue factor pathway in the biology of tumor initiating cells
Garnier, D., Milsom, C., Magnus, N., Meehan, B., Weitz, J. I., Yu, J., & Rak, J. W. (2010) · Thrombosis Research · doi:10.1016/s0049-3848(10)70012-8 · Cited by 43
Jain, R., Poisson, L., Narang, J., Scarpace, L. M., Rosenblum, M. L., Rempel, S. A., & Mikkelsen, T. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2956 · Cited by 43
Hu, J., Yin, Z., Shen, W., Xie, Y., Zhu, T., Lü, P., Cai, Y., Kong, M., Heng, B. C., Zhou, Y., et al. (2016) · Stem Cells · doi:10.1002/stem.2306 · Cited by 43
Ye, X., Wang, G., Gui-jun, H., Bian, X., Qian, G., & Yu, S. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9122-9 · Cited by 44
Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy
Sen, E. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.003 · Cited by 42
Enrichment of cancer stem cell-like cells by culture in alginate gel beads
Xu, X., Liu, C. X., Yang, L., Li, Y., Li, N., Guo, X. W., Sun, G., & Ma, X. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.02.016 · Cited by 45
The roles of ncRNAs and histone-modifiers in regulating breast cancer stem cells
Zhao, Z., Li, S., Song, E., & Liu, S. (2015) · Protein & Cell · doi:10.1007/s13238-015-0199-4 · Cited by 42
CD73 as a therapeutic target for pancreatic neuroendocrine tumor stem cells
Katsuta, E., Tanaka, S., Mogushi, K., Shimada, S., Akiyama, Y., Aihara, A., Matsumura, S., Mitsunori, Y., Ban, D., Ochiai, T., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3299 · Cited by 44
Iwadate, Y., Matsutani, T., Hirono, S., Shinozaki, N., & Saeki, N. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2145-6 · Cited by 42
Maciaczyk, D., Picard, D. J., Zhao, L., Koch, K., Herrera-Rios, D., Li, G., Marquardt, V., Pauck, D., Hörbelt, T., Zhang, W., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.157 · Cited by 42
The viable circulating tumor cells with cancer stem cells feature, where is the way out?
Luo, Y., Cheng, J. Q., Feng, X., He, S., Wang, Y., & Huang, Q. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0685-7 · Cited by 43
Hallal, S. M., Ebrahimkhani, S., Shivalingam, B., Graeber, M. B., Alexander, K. L., & Buckland, M. E. (2019) · Brain Tumor Pathology · doi:10.1007/s10014-019-00335-0 · Cited by 42
Yuan, Y., Yan, Z., Miao, J., Cai, R., Zhang, M., Wang, Y., Wang, L., Dang, W., Wang, D., Xiang, D., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1467-7 · Cited by 42
Nanomedicines Targeting Glioma Stem Cells
Sabu, A., Liu, T., Ng, S. S., Doong, R., Huang, Y., & Chiu, H. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c03538 · Cited by 46
Richter, S., Qin, N., Pacak, K., & Eisenhofer, G. (2013) · Advances in Pharmacology · doi:10.1016/b978-0-12-411512-5.00014-2 · Cited by 42
Hypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise
Abd, G. M., Laird, M. C., Ku, J. C., & Li, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1227884 · Cited by 41
Niklasson, C. U., Fredlund, E., Monni, E., Lindvall, J. M., Kokaia, Z., Hammarlund, E. U., Bronner-Fraser, M. E., & Mohlin, S. (2020) · Developmental Dynamics · doi:10.1002/dvdy.253 · Cited by 42
Ho, K., Shih, C.-M., Liu, A.-J., & Chen, K. (2021) · Cancer Science · doi:10.1111/cas.15240 · Cited by 41
Regulation of Stem Cell Plasticity: Mechanisms and Relevance to Tissue Biology and Cancer
Strauss, R., Hamerlik, P., Lieber, A., & Bartek, J. (2012) · Molecular Therapy · doi:10.1038/mt.2012.2 · Cited by 41
Bhagat, M., Palanichamy, J. K., Ramalingam, P., Mudassir, M., Irshad, K., Chosdol, K., Sarkar, C., Seth, P., Goswami, S., Sinha, S., et al. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.02.017 · Cited by 41
Hira, V. V. V., Breznik, B., Vittori, M., de Jong, A. L., Mlakar, J., Oostra, R., Khurshed, M., Molenaar, R. J., Lah, T. T., & Noorden, C. J. F. V. (2019) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155419878416 · Cited by 41
Patient-Derived Cancer Organoids for Precision Oncology Treatment
Pernik, M. N., Bird, C. E., Traylor, J. I., Shi, D. D., Richardson, T. E., McBrayer, S. K., & Abdullah, K. G. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050423 · Cited by 46
A vascular perspective on neuronal migration
Segarra, M., Kirchmaier, B. C., & Acker‐Palmer, A. (2015) · Mechanisms of Development · doi:10.1016/j.mod.2015.07.004 · Cited by 43
Oct‐3/4 promotes migration and invasion of glioblastoma cells
Kobayashi, K., Takahashi, H., Inoue, A., Harada, H., Toshimori, S., Kobayashi, Y., Katsuhiro, G. O. T. O., Sugimoto, K., Yano, H., Ohnishi, T., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23374 · Cited by 43
Hypoxia-inducible factor 2α: a novel target in gliomas
Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0163 · Cited by 40
Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis
Chanoch-Myers, R., Wider, A., Suvà, M. L., & Tirosh, I. (2022) · Genome Medicine · doi:10.1186/s13073-022-01109-8 · Cited by 40
Strowd, R. E., III, Ellingson, B. M., Raymond, C., Yao, J., Wen, P. Y., Ahluwalia, M. S., Piotrowski, A. F., Desai, A. S., Clarke, J. L., Lieberman, F. S., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04456-7 · Cited by 40
Liu, T., Wang, X., Bai, Y., Liao, H., Qiu, S., Yang, Y., Yan, X., Chen, J., Guo, H.-B., & Zhang, S. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.01.007 · Cited by 40
Selbo, P. K., Bostad, M., Olsen, C. E., Edwards, V. T., Høgset, A., Weyergang, A., & Berg, K. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c5pp00027k · Cited by 41
Gene and Viral Therapy for Glioblastoma
Mohyeldin, A., & Chiocca, E. A. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182458b13 · Cited by 40
The Potent Inhibitory Effect of a Naproxen‐Appended Cobalt(III)‐Cyclam Complex on Cancer Stem Cells
Cressey, P., Eskandari, A., Bruno, P. M., Lü, C., Hemann, M. T., & Suntharalingam, K. (2016) · ChemBioChem · doi:10.1002/cbic.201600368 · Cited by 40
Nanomedicine Strategies for sustained, Controlled and Targeted Treatment of Cancer Stem Cells
Gao, J., Li, W., Guo, Y., & Feng, S. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0261 · Cited by 40
Lee, D.-H., Oh, S. C., Giles, A. J., Jung, J., Gilbert, M. R., & Park, D. M. (2017) · Oncotarget · doi:10.18632/oncotarget.16714 · Cited by 40
Catalase‐Functionalized Iron Oxide Nanoparticles Reverse Hypoxia‐Induced Chemotherapeutic Resistance
Yen, T., Stephen, Z. R., Lin, G., Mu, Q., Jeon, M., Untoro, S., Welsh, P., & Zhang, M. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900826 · Cited by 41
Kang, H., Lee, H., Kim, D., Kim, B., Kang, J., Kim, H. Y., Youn, H., & Youn, B. (2022) · Biomedicines · doi:10.3390/biomedicines10061308 · Cited by 40
Cell Fusion Hypothesis of the Cancer Stem Cell
Lü, X., & Kang, Y. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-0782-5_6 · Cited by 41
Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling
Alvarado, A. G., Turaga, S. M., Sathyan, P., Mulkearns-Hubert, E. E., Otvos, B., Silver, D. J., Hale, J. S., Flavahan, W. A., Zinn, P. O., Sinyuk, M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov196 · Cited by 40
Self-citationMigrating glioma cells express stem cell markers and give rise to new tumors upon xenografting
Munthe, S., Sørensen, M. D., Thomassen, M., Burton, M., Kruse, T. A., Lathia, J. D., Poulsen, F. R., & Kristensen, B. W. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2221-y · Cited by 39
Self-citationGlioblastoma and glioblastoma stem cells are dependent on functional MTH1
Pudelko, L., Rouhi, P., Sanjiv, K., Gad, H., Kalderén, C., Höglund, A., Squatrito, M., Schuhmacher, A. J., Edwards, S. J., Hägerstrand, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19404 · Cited by 41
Metadata
- Authors
- Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N.
- Affiliations
- Duke Medical Center (US)
- Cleveland Clinic (US)
- Corresponding author
- Rich, Jeremy N.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 15
- Issue
- 6
- Pages
- 501-513
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2693960
- OpenAlex
- W2039075677
- Cited by
- 1,354
- References
- 65
- Citations by year
- 2026: 41 · 2025: 40 · 2024: 49 · 2023: 72 · 2022: 92 · 2021: 98 · 2020: 72 · 2019: 75 · 2018: 74 · 2017: 93 · 2016: 97 · 2015: 97 · 2014: 96 · 2013: 80 · 2012: 101
- FWCI
- 30.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA 116659, R01CA116659, CA112958, R01CA129958)
- National Institute of Neurological Disorders and Stroke (K02NS047409, R01NS054276, NS054276, NS047409)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- HIF-2α, glioma stem cells, glioblastoma, hypoxia, angiogenesis, self-renewal, tumor initiation, cancer stem cell markers, patient survival, therapeutic target
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Animals, Brain Neoplasms, Cell Survival, Cells, Cultured, Glioblastoma, Humans, Mice, Inbred BALB C, Mice, Nude, Neoplasm Transplantation, Neovascularization, Pathologic, Stem Cells, Biomarkers, Tumor, Neoplastic Stem Cells, Cell Hypoxia, Vascular Endothelial Growth Factor A, Cell Proliferation, Mice, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
